Table 1

Baseline Characteristics According to Final LV Lead Position

All Patients
(n = 250)
Concordant/Adjacent
LV Lead
(n = 202)
Remote
LV Lead
(n = 48)
p Value
Age, yrs72 (64–77)71 (63–77)74 (69–79)0.02
Male193 (77)152 (75)41 (85)0.18
NYHA functional class IV30 (12)22 (11)8 (17)0.5
Ischemic etiology135 (54)107 (53)28 (58)0.5
Cardiac parameters
 QRS duration, ms157 (146–170)160 (146–176)155 (136–171)0.09
 LVEDV, ml187 (152–220)187 (152–223)190 (152–213)0.8
 LVESV, ml143 (112–175)143 (112–177)140 (119–165)0.85
 LVEF, %23 (19–29)24 (19–29)23 (18–29)0.6
 LV filling time, ratio0.4 (0.35–0.46)0.4 (0.34–0.46)0.4 (0.35–0.5)0.45
 IVMD, ms40 (22–57)40 (22–57)39 (20–66)0.64
 AS-PW delay, ms167 (56–324)193 (68–321)110 (26–240)0.08
Treatment history
 ACEI or ARB232 (93)189 (94)43 (90)0.4
 Beta-blocker178 (71)144 (71)34 (71)0.95
 Spironolactone140 (56)116 (57)24 (50)0.4
 CRTD92 (37)77 (38)15 (31)0.5

Values are median (interquartile range) or n (%). p Value for comparison of concordant/adjacent and remote groups.

ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; AS-PW = anteroseptal to posterior wall delay; CRTD = cardiac resynchronization therapy defibrillator; IVMD = interventricular mechanical delay; LV = left ventricular; LVEDV = left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic volume; NYHA = New York Heart Association functional classification.